News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
576,415 Results
Type
Article (51028)
Company Profile (127)
Press Release (525258)
Multimedia
Podcasts (91)
Webinars (16)
Section
Business (156161)
Career Advice (2458)
Deals (29130)
Drug Delivery (122)
Drug Development (71625)
Employer Resources (154)
FDA (15930)
Job Trends (12616)
News (280374)
Policy (30685)
Tag
Academia (2667)
Academic (1)
Accelerated approval (7)
Adcomms (32)
Allergies (93)
Alliances (40135)
ALS (101)
Alzheimer's disease (1534)
Antibody-drug conjugate (ADC) (160)
Approvals (15868)
Artificial intelligence (296)
Autoimmune disease (30)
Automation (15)
Bankruptcy (318)
Best Places to Work (9738)
BIOSECURE Act (22)
Biosimilars (119)
Biotechnology (77)
Bladder cancer (90)
Brain cancer (33)
Breast cancer (338)
Cancer (2621)
Cardiovascular disease (214)
Career advice (2060)
Career pathing (33)
CAR-T (181)
CDC (33)
Cell therapy (481)
Cervical cancer (22)
Clinical research (58578)
Collaboration (875)
Company closure (3)
Compensation (625)
Complete response letters (29)
COVID-19 (2684)
CRISPR (59)
C-suite (277)
Cystic fibrosis (106)
Data (2623)
Decentralized trials (2)
Denatured (16)
Depression (61)
Diabetes (300)
Diagnostics (5699)
Digital health (18)
Diversity (4)
Diversity, equity & inclusion (43)
Drug discovery (118)
Drug pricing (142)
Drug shortages (34)
Duchenne muscular dystrophy (117)
Earnings (61378)
Editorial (48)
Employer branding (20)
Employer resources (140)
Events (84361)
Executive appointments (763)
FDA (17431)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (801)
Gene editing (126)
Generative AI (23)
Gene therapy (376)
GLP-1 (833)
Government (4127)
Grass and pollen (6)
Guidances (174)
Healthcare (16111)
Huntington's disease (28)
IgA nephropathy (37)
Immunology and inflammation (164)
Immuno-oncology (7)
Indications (31)
Infectious disease (2845)
Inflammatory bowel disease (146)
Inflation Reduction Act (10)
Influenza (56)
Intellectual property (104)
Interviews (452)
IPO (14461)
IRA (50)
Job creations (3259)
Job search strategy (1712)
Kidney cancer (14)
Labor market (43)
Layoffs (541)
Leadership (24)
Legal (7220)
Liver cancer (78)
Lung cancer (367)
Lymphoma (189)
Machine learning (9)
Management (53)
Manufacturing (348)
MASH (87)
Medical device (11722)
Medtech (11725)
Mergers & acquisitions (15305)
Metabolic disorders (818)
Multiple sclerosis (91)
NASH (22)
Neurodegenerative disease (123)
Neuropsychiatric disorders (36)
Neuroscience (2178)
NextGen: Class of 2025 (5369)
Non-profit (3758)
Now hiring (25)
Obesity (443)
Opinion (244)
Ovarian cancer (93)
Pain (106)
Pancreatic cancer (101)
Parkinson's disease (174)
Partnered (17)
Patents (271)
Patient recruitment (126)
Peanut (48)
People (47201)
Pharmaceutical (37)
Pharmacy benefit managers (24)
Phase I (17796)
Phase II (25457)
Phase III (20367)
Pipeline (1527)
Policy (210)
Postmarket research (2333)
Preclinical (7410)
Press Release (38)
Prostate cancer (132)
Psychedelics (36)
Radiopharmaceuticals (233)
Rare diseases (465)
Real estate (4687)
Recruiting (61)
Regulatory (21747)
Reports (35)
Research institute (2474)
Resumes & cover letters (409)
Rett syndrome (9)
RNA editing (6)
RSV (51)
Schizophrenia (88)
Series A (138)
Series B (90)
Service/supplier (9)
Sickle cell disease (63)
Special edition (20)
Spinal muscular atrophy (135)
Sponsored (35)
Startups (3049)
State (1)
Stomach cancer (16)
Supply chain (76)
Tariffs (63)
The Weekly (74)
Vaccines (838)
Venture capitalists (51)
Weight loss (304)
Women's health (35)
Worklife (20)
Date
Today (27)
Last 7 days (456)
Last 30 days (2212)
Last 365 days (29912)
2025 (14354)
2024 (32641)
2023 (36457)
2022 (46794)
2021 (50506)
2020 (47766)
2019 (38964)
2018 (29490)
2017 (29384)
2016 (27842)
2015 (30549)
2014 (24106)
2013 (19975)
2012 (21312)
2011 (21661)
2010 (19655)
Location
Africa (731)
Alabama (52)
Alaska (6)
Arizona (189)
Arkansas (11)
Asia (34139)
Australia (6124)
California (6614)
Canada (1815)
China (520)
Colorado (272)
Connecticut (301)
Delaware (176)
Europe (82019)
Florida (1022)
Georgia (214)
Hawaii (1)
Idaho (41)
Illinois (539)
India (26)
Indiana (311)
Iowa (15)
Japan (200)
Kansas (92)
Kentucky (18)
Louisiana (10)
Maine (66)
Maryland (949)
Massachusetts (4933)
Michigan (198)
Minnesota (373)
Mississippi (2)
Missouri (75)
Montana (16)
Nebraska (20)
Nevada (69)
New Hampshire (59)
New Jersey (1844)
New Mexico (19)
New York (1843)
North Carolina (996)
North Dakota (8)
Northern California (2950)
Ohio (196)
Oklahoma (10)
Oregon (30)
Pennsylvania (1401)
Puerto Rico (11)
Rhode Island (25)
South America (1107)
South Carolina (32)
South Dakota (1)
Southern California (2472)
Tennessee (105)
Texas (963)
United States (24358)
Utah (182)
Virginia (162)
Washington D.C. (73)
Washington State (557)
West Virginia (4)
Wisconsin (67)
576,415 Results for "banner alzheimer s institute".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Alzheimer’s disease
FDA Clears First Alzheimer’s Blood Test, Lending ‘Momentum’ to Lilly’s Kisunla, Biogen’s Leqembi
Analysts at BMO Capital Markets said in a weekend note that a non-invasive blood test could help boost uptake of Alzheimer’s disease therapies.
May 19, 2025
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
Cassava Finally Ends Alzheimer’s Program for Embattled Simufilam
After years of controversy and allegations of doctored data, Cassava is moving on from Alzheimer’s.
March 25, 2025
·
1 min read
·
Annalee Armstrong
Press Releases
NIH awards Feinstein Institutes $2 million to study impact of heat, stroke on people with Alzheimer’s disease
April 16, 2025
·
3 min read
Mergers & acquisitions
Sanofi Buys Vigil for $470M Upfront, Reigniting a Battered Alzheimer’s Target
The deal helps revitalize the TREM2 target after the high-profile failure of AbbVie and Alector’s candidate last year.
May 22, 2025
·
4 min read
·
Annalee Armstrong
Alzheimer’s disease
Vigil’s TREM2-Targeted Alzheimer’s Treatment Shows Early Promise, Moves On to Phase II
Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new avenue for treating Alzheimer’s disease.
January 23, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
Davos Alzheimer’s Collaborative Selects PacBio as Technology Partner for Global Project to Advance Alzheimer’s Disease Research in North Africa
April 22, 2025
·
10 min read
Neurodegenerative disease
7 Alzheimer’s and Parkinson’s Programs Discarded in 2024
This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are still chasing these multi-billion-dollar markets.
November 4, 2024
·
6 min read
·
Heather McKenzie
GLP-1
Evidence Mounts for Potential of GLP-1s in Alzheimer’s Disease
The darlings of the weight loss and diabetes spaces, GLP-1 receptor agonists have shown promise against Alzheimer’s in recent studies—with Phase III results expected next year from Novo Nordisk.
December 9, 2024
·
6 min read
·
Heather McKenzie
Press Releases
Cognito Therapeutics Announces Non-invasive Neuromodulation Therapy Delays Alzheimer’s Disease Progression
June 11, 2025
·
4 min read
Alzheimer’s disease
Cassava’s Shares Plunge as Alzheimer’s Drug Fails Phase III
Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had pledged to share the results whether “good, bad or ambiguous.”
November 25, 2024
·
2 min read
·
Annalee Armstrong
1 of 57,642
Next
